The emergence of antibiotic resistant microorganisms, lethal viruses and the threat of engineered microorganism have newly stimulated the interest in recombinant antibodies for infectious diseases. Advances in understanding pathogenetic mechanisms and new antibody technologies have further contributed to a growing class of anti-infective antibodies. Apart from recombinant mono- or polyclonal antibodies, human plasma-derived immunoglobulins have their place in the treatment of immunedeficiencies and specific immunoglobulins (hyperimmunes) are part of standard protocols in post-exposure prophylaxis of a number of infectious diseases. Modern plasma-derived immunoglobulins are characterized by improved purification procedures, more convenience (room temperature stable, ready-to-use preparations, new stabilizers, higher concentrated) and new developments.
The report includes a compilation of product portfolios and current active projects in research and development of anti-infective antibodies and immunoglobulins. In addition, the report lists company-specific R&D pipelines product portfolios anti-infective antibodies, immunoglobulins and hyperimmunes. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79162/competitor-analysis-anti-infective-antibodies-.html
Saturday, 2 June 2012
HIV Small Molecule Therapeutics Competitor Analysis - Latest Report
The present Competitive Intelligence report about HIV Small Molecule Therapeutics used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed products and R&D projects of HIV small molecule therapeutics as of December 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of marketed products and currently active projects in research and development of HIV Small Molecule Therapeutics. In addition, the report lists company-specific product portfolios and R&D pipelines of HIV Small Molecule Therapeutics. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79161/hiv-small-molecule-therapeutics-competitor-analysis.html
The report includes a compilation of marketed products and currently active projects in research and development of HIV Small Molecule Therapeutics. In addition, the report lists company-specific product portfolios and R&D pipelines of HIV Small Molecule Therapeutics. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79161/hiv-small-molecule-therapeutics-competitor-analysis.html
Antibody-Drug Conjugates (ADC) Competitor Analysis - Latest Report
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of December 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79160/antibody-drug-conjugates-adc-competitor-analysis.html
The report includes a compilation of current active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79160/antibody-drug-conjugates-adc-competitor-analysis.html
Cardiovascular Peptides Competitor Analysis - Latest Report
The present Competitive Intelligence Report about Cardiovascular Peptides used to treat or prevcent heart failure, myocardial infarction, thrombosis, arrhythmias, hypertension, peripheral and cerebral vascular diseases, and hematologic disorders provides a competitor evaluation in the field of R&D projects with cardiovascular peptides as of December 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of cardiovasuclar peptides. In addition, the report lists company-specific R&D pipelines of cardiovascular peptides. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79159/cardiovascular-peptides-competitor-analysis.html
The report includes a compilation of current active projects in research and development of cardiovasuclar peptides. In addition, the report lists company-specific R&D pipelines of cardiovascular peptides. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79159/cardiovascular-peptides-competitor-analysis.html
Anti-Infective Peptides Competitor Analysis- Latest Report
The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of December 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Anti-Viral Peptides
Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).
Anti-Bacterial Peptides
Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram+ and gram- infections, prevention of catheter-related infections, otitis media, gingivitis and many more.
Anti-Fungal Peptides
Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more
The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79158/anti-infective-peptides-competitor-analysis.html
Anti-Viral Peptides
Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).
Anti-Bacterial Peptides
Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram+ and gram- infections, prevention of catheter-related infections, otitis media, gingivitis and many more.
Anti-Fungal Peptides
Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more
The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79158/anti-infective-peptides-competitor-analysis.html
Anti-Obesity Biologics Competitor Analysis - Latest Report
The present Competitive Intelligence Report about Anti-Obesity Peptides and Biologics used to treat obesity and metabolic syndrome provides a competitor evaluation in the field of R&D projects with anti-obesity peptides and biologics as of February 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of anti-obesity peptides and biologics such as proteins, antibodies, vaccines, cells, and RNA. In addition, the report lists company-specific R&D pipelines of anti-obesity peptides and biologics. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79157/anti-obesity-biologics-competitor-analysis.html
The report includes a compilation of current active projects in research and development of anti-obesity peptides and biologics such as proteins, antibodies, vaccines, cells, and RNA. In addition, the report lists company-specific R&D pipelines of anti-obesity peptides and biologics. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79157/anti-obesity-biologics-competitor-analysis.html
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists A Target Pipeline and Stakeholder Analysis 2012
This report ""Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012"" published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A comprehensive analysis of the state of the art and key trends guides the reader through this emerging antidiabetic drug class. Scientific and technological approaches as well as molecules in the target pipeline of GLP-1 receptor agonists are described and assessed. A critical appraisal of the clinical results of advanced GLP-1 receptor agonist projects and products is provided..
Scope of the report
Commercial experience with incretin-based therapeutics
Monthly treatment costs of GLP-1R agonists
Physician preferences and priorities for GLP-1R agonists
GLP-1R agonist market drivers and restraints
Unmet needs and differentiation between GLP-1R agonists
Valuation of GLP-1R agonist programs by business transactions
Next-to-market GLP-1R agonists
Once-daily subcutaneous GLP-1R agonists
Long-acting subcutaneous GLP-1R agonists
Non-invasive peptide GLP-1R agonists
Oral small molecule GLP-1R agonists
Combinatgion and dual target Glucagon/GIP and GLP-1R agonists
Although the first glucagon-like peptide-1 receptor (GLP-1R) agonist was already approved in 2005, it was the launch of the once daily GLP-1R agonist Victoza from Novo Nordisk in 2010 which boosted the market size to US$ 1.7 bln in 2011. Victoza became a blockbuster in its second year on the market. The unique feature of weight reduction associated with the use GLP-1R agonists clearly differentiates this antidiabetic drug class from other established antidiabetics. The profound blood glucose lowering effect without significant hypoglycemia made GLP-1R agonists to a strongly emerging antidiabetic drug class. Gastrointestinal side effects such as nausea, vomiting and diarrhea seem to be associated with the pharmacologic effect of GLP-1R agonism.
The clinically and commercially validated target makes GLP-1 attractive for follow-on molecules with improved properties. Analysis of the GLP-1R agonist pipeline revealed in addition to the three approved and marketed GLP-1R agonists (Byetta, Victoza and once-weekly Bydureon) 66 R&D projects including eight life cycle versions. The vast majority of new GLP-1R agonists are designed to have improved features which mainly are based on convenience (less frequent administration or non-invasive/oral administration). Molecules with less frequent subcutaneous administration make out the majority (33) with 13 projects in clinical phases II or III, while 18 R&D projects are directed to non-invasive or oral administration of GLP-1R agonists with only one program in phase II. A strongly emerging third cluster of novel GLP-1 R agonists is that of GLP-1R agonists in combination with insulin at a fixed ratio and of co-agonists or dual targeting molecules, i.e. GLP-1R agonists which also act at the receptor of glucagon (mostly) or GIP.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79156/glucagon-like-peptide-1-glp-1-receptor-agonists-a-target-pipeline-and-stakeholder-analysis-2012.html
Scope of the report
Commercial experience with incretin-based therapeutics
Monthly treatment costs of GLP-1R agonists
Physician preferences and priorities for GLP-1R agonists
GLP-1R agonist market drivers and restraints
Unmet needs and differentiation between GLP-1R agonists
Valuation of GLP-1R agonist programs by business transactions
Next-to-market GLP-1R agonists
Once-daily subcutaneous GLP-1R agonists
Long-acting subcutaneous GLP-1R agonists
Non-invasive peptide GLP-1R agonists
Oral small molecule GLP-1R agonists
Combinatgion and dual target Glucagon/GIP and GLP-1R agonists
Although the first glucagon-like peptide-1 receptor (GLP-1R) agonist was already approved in 2005, it was the launch of the once daily GLP-1R agonist Victoza from Novo Nordisk in 2010 which boosted the market size to US$ 1.7 bln in 2011. Victoza became a blockbuster in its second year on the market. The unique feature of weight reduction associated with the use GLP-1R agonists clearly differentiates this antidiabetic drug class from other established antidiabetics. The profound blood glucose lowering effect without significant hypoglycemia made GLP-1R agonists to a strongly emerging antidiabetic drug class. Gastrointestinal side effects such as nausea, vomiting and diarrhea seem to be associated with the pharmacologic effect of GLP-1R agonism.
The clinically and commercially validated target makes GLP-1 attractive for follow-on molecules with improved properties. Analysis of the GLP-1R agonist pipeline revealed in addition to the three approved and marketed GLP-1R agonists (Byetta, Victoza and once-weekly Bydureon) 66 R&D projects including eight life cycle versions. The vast majority of new GLP-1R agonists are designed to have improved features which mainly are based on convenience (less frequent administration or non-invasive/oral administration). Molecules with less frequent subcutaneous administration make out the majority (33) with 13 projects in clinical phases II or III, while 18 R&D projects are directed to non-invasive or oral administration of GLP-1R agonists with only one program in phase II. A strongly emerging third cluster of novel GLP-1 R agonists is that of GLP-1R agonists in combination with insulin at a fixed ratio and of co-agonists or dual targeting molecules, i.e. GLP-1R agonists which also act at the receptor of glucagon (mostly) or GIP.
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79156/glucagon-like-peptide-1-glp-1-receptor-agonists-a-target-pipeline-and-stakeholder-analysis-2012.html
Subscribe to:
Posts (Atom)